Author: accesswire

RALEIGH NC / ACCESS Newswire / August 28, 2025 / ACCESS Newswire Inc. (NYSE American:ACCS), an industry-leading communications company, announced today that management will participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference on September 11, 2025. The conference is being held at The Yale Club in New York City.

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or james@haydenir.com.

About Access Newswire
We are ACCESS Newswire, a global trusted Public Relations (PR) and Investor Relations (IP) solution provider. With a focus on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands to connect with their audience where it matters most. From start-ups to multi-billion-dollar global brands, we ensure your most important moments make an impact and resonate with your audiences. To learn more visit www.accessnewswire.com.

Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the Company’s expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “commit,” “estimate,” “predict,” “potential,” “outlook,” “guidance,” “target,” “goal,” “project,” “continue to,” “confident,” or the negative of those terms or other comparable terminology. The forward-looking statements in this press release include, among other things, our confidence that our shift from pay-as-you-go to a subscription-based model is building the sustainable, predictable business we have been working toward and our belief that our various initiatives will further strengthen our performance and drive improved results in both the near and long-term.

Please see the Company’s documents filed or to be filed with the Securities and Exchange Commission at www.sec.gov, including the Company’s Annual Reports filed on Form 10-K, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Reports on Form 10-Q, and any amendments thereto for a discussion of certain important risk factors that relate to forward-looking statements contained in this report. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Any forward-looking statements are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For Further Information:

ACCESS Newswire Inc.
Brian R. Balbirnie: 919-481-4000
brianb@accessnewswire.com

Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: ACCESS Newswire Inc.

View the original press release on ACCESS Newswire

In vitro findings reveal Telomir-1’s dual action: targeting DNA methylation switches and cutting into the Wnt “fuel line” that drives cancer growth.

MIAMI, FLORIDA / ACCESS Newswire / August 28, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root mechanisms of cancer, aging, and age-related diseases, today announced new in vitro results that expand understanding of its lead drug candidate, Telomir-1.

In studies conducted by Eurofins Discovery, Telomir-1 was shown to potently inhibit UTX (KDM6A), an enzyme that acts like an “eraser” of chemical tags on DNA packaging proteins. These tags, known as DNA methylation and histone marks, are part of the body’s system for deciding which genes are turned on or off – much like switches on a circuit board.

When UTX activity is abnormal, it can silence protective genes and activate harmful ones, a pattern commonly seen in cancer, autoimmune disease, and neurodegeneration. Beyond cancer, UTX has also been linked to the biology of aging itself. Studies show that UTX influences stem cell renewal, reprogramming, and differentiation – meaning it helps control how effectively tissues can repair themselves as we age. UTX works in close connection with DNA methylation, and when this coordination breaks down it can lead to epigenetic drift – the gradual loss of proper gene regulation that occurs with aging and underlies many chronic diseases, including cancer, autism spectrum disorder, neurodegeneration, and metabolic dysfunction.

Because UTX has long been considered undruggable, Telomir-1’s ability to block it is a major step forward. By doing so, Telomir-1 may help reset faulty DNA methylation patterns, restore proper gene control, support stem cell function, and counteract age-related epigenetic drift – reawakening the body’s natural defenses against both disease and decline.

“Everything from cancer to aging to autism has been linked to faulty DNA methylation. Telomir-1 is capable to jointly reset several of those methylation patterns – which could make it one of the first drugs to address the root biology driving so many diseases,” said Erez Aminov, CEO of Telomir.

Extending the Epigenetic Reset Profile

As previously reported, Telomir-1 was also shown to inhibit other faulty epigenetic enzymes that play critical roles in DNA methylation, gene regulation, cancer, neurodegeneration, metabolic dysfunction, inflammation, and aging:

• FBXL10 (KDM2B) – Frequently overactive in aggressive cancers such as leukemia, breast, and pancreatic, where it allows tumors to maintain “stem-like” properties that drive relapse and treatment resistance. FBXL10 also influences DNA methylation dynamics and is linked to metabolic and inflammatory pathways.

• FBXL11 (KDM2A) – Elevated in lung, gastric, and ovarian cancers, where it helps tumors grow and evade immune detection. FBXL11 regulates chromatin and DNA methylation patterns and has also been linked in the literature to autism spectrum disorder and glucose control dysfunction, underscoring its role in both cancer and metabolic disease.

• JMJD3 (KDM6B) – A major regulator of inflammation and tumor progression, overexpressed in prostate, glioma, and ovarian cancers. By altering histone marks that interact with DNA methylation, JMJD3 fuels metastasis and helps cancers escape immune attack. Beyond oncology, JMJD3 drives chronic inflammation in autoimmune and neurodegenerative diseases such as lupus and Alzheimer’s, by switching on cytokines like IL-6 and IL-4.

In those earlier studies, Telomir-1 also reactivated silenced tumor suppressor genes such as STAT1 and TMS1 in prostate cancer models by reversing abnormal DNA methylation, providing functional evidence of its ability to reset faulty gene programs.

Taken together, these findings – now strengthened by Telomir-1’s new UTX data – support its emerging profile as a broad epigenetic reset therapy that may:

• Help reawaken tumor suppressor genes (STAT1, TMS1).

• Block cancer’s growth enablers (FBXL10/11).

• Dial down inflammation (JMJD3/UTX).

• Support more youthful patterns of gene regulation across multiple disease pathways.

Selectivity Advantage

Importantly, Telomir-1 did not show any activity against GCN5L2 (KAT2A), a broad acetyltransferase enzyme, whose inhibition is associated with widespread toxicity. This selective profile may allow Telomir-1 to achieve its effects with a cleaner safety margin than many existing epigenetic drugs.

Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, added “UTX and JMJD3 have long been labeled undruggable despite their central role in cancer, inflammation, and aging. The fact that Telomir-1 engages both enzymes with high potency, while sparing opposing targets such as GCN5L2, is a significant mechanistic breakthrough. It highlights Telomir-1’s potential to reprogram gene control selectively and safely.”

Added Anti-Cancer Synergy: Cutting Off Cancer’s Fuel Line – With a Safety Advantage

Telomir-1 also demonstrated low-level inhibitory activity against Tankyrases (PARP5A and PARP5B). Tankyrases regulate the Wnt/β-catenin pathway – one of the body’s key growth-control circuits that cancers often hijack as a “fuel line” for unchecked growth and treatment resistance.

Unlike potent Tankyrase inhibitors, which can cause excessive telomere shortening and systemic toxicity, Telomir-1’s modest Tankyrase inhibition may provide just enough activity to cut off cancer’s fuel line without disrupting healthy telomere biology.

Importantly, previously reported results in a validated Werner Syndrome accelerated-aging model showed that Telomir-1 significantly elongated telomeres beyond healthy levels while also reversing abnormal DNA methylation, restoring youthful gene regulation, and resetting the body’s epigenetic clock. This distinction reinforces Telomir-1’s differentiated safety profile – demonstrating that, unlike other Tankyrase-targeting drugs, it may protect and lengthen telomeres rather than shorten them.

Why This Matters and Potential Implications

The implications of this mechanism are broad:

• Cancer: May help reawaken tumor-fighting genes and inhibit pathways that drive proliferation, metastasis, and resistance – while safely tapping into Wnt/Tankyrase signaling to cut off cancer’s “fuel line.”

• Autoimmune & Inflammatory Disorders: May help calm runaway immune responses by dialing down inflammatory cytokines such as IL-6 and IL-4.

• Neurodegeneration: May help reduce harmful neuroinflammation and restore balance in brain-related gene programs relevant to Alzheimer’s and other CNS disorders.

• Autism & Neurodevelopment: Abnormal DNA methylation patterns have been associated with autism spectrum disorder, and Telomir-1’s inhibition of FBXL11 – a methylation-linked enzyme tied to neurodevelopment – suggests potential to help restore healthier gene regulation in ASD and related conditions.

• Metabolic Dysfunction: May help improve glucose control and insulin sensitivity in type 2 diabetes by rebalancing metabolic gene networks.

• Healthy Aging: By shifting gene programs back toward youthful patterns – and extending telomeres in vivo – Telomir-1 may one day support healthier aging and potentially aspects of age reversal.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

Bringing Together Dealmakers Driving the Future of Private Investments in Public Equity

NEW YORK, NY / ACCESS Newswire / August 28, 2025 / DealFlow Events today announced the agenda for the 2025 PIPEs Conference, the premier gathering focused on private investments in public equity (PIPEs). Taking place in Hollywood, Florida, the conference brings together thought leaders, dealmakers, and investors to discuss the evolving role of PIPEs in corporate finance.

PIPE transactions remain an important source of capital for public companies navigating volatile markets, with investors and issuers continuing to look to this structure for speed, flexibility, and access to growth capital.

This year’s speaking faculty includes leaders from Loeb & Loeb, Roth Capital, Ellenoff Grossman & Schole, Sheppard Mullin, Katten, WilmerHale, Sichenzia Ross Ference Carmel, McDermott Will & Schulte, and Baker McKenzie-alongside other executives and investors who are driving the PIPEs market.

The full agenda, now available online, covers the latest legal, regulatory, and market developments shaping PIPEs in 2025. Topics include deal structuring, compliance trends, and the outlook for issuers and investors amid shifting economic conditions.

Members of the press are invited to attend.

For more information and to view the agenda, visit www.thepipesconference.com.

Contact:

Phillip LoFaso
Managing Director
DealFlow Events
phillip@dealflowevents.com
(516) 876-8006

SOURCE: DealFlow Events

View the original press release on ACCESS Newswire

VANCOUVER, BC / ACCESS Newswire / August 28, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to announce the completion of its 2025 sonic drilling and bulk sampling testing programme at the Lac Jeannine Iron Tailings Project, Québec, Canada (“Lac Jeannine”, or the “Project”). The Company has engaged Corem to complete the metallurgical testing and has commenced a process to appoint a EPCM provider for the Feasibility Study. The Feasibility Study is expected to commence in Q3, 2025.

Julian Treger, CoTec CEO commented; “CoTec has progressed its discussions with strategic partners to move rapidly onto preparation of a Feasibility Study with the support of all stakeholders, including the Government of Québec, First Nations and other interested parties. The results from this next phase of drilling and bulk sample collection will allow CoTec to increase its current resource estimate for Lac Jeannine and potentially unlock additional material outside of the tailings dam to reprocess.

The Company is very excited to commence a Feasibility Study regarding the recovery and production of critical mineral iron ore concentrate at competitive cost structures which can deliver high purity iron concentrates for the green steel industry. The Lac Jeannine Project offers great potential for the resource industry to recover the economic benefit of large Fe tailing sites.”

In June 2024 CoTec announced the completion of an initial Mineral Resource Estimate (the “MRE”) and positive Preliminary Economic Assessment (“PEA”) for the Project^[i]. Based on open-pit extraction methods and the production of a gravity concentrate via conventional processing techniques and at a discount rate of 7.0% (and based solely on the MRE), the pre-tax NPV is US$93.6M, and its IRR is 38%, and the after tax NPV is US$59.5M, and its IRR is 30%. As part of the Feasibility Study, the Company is including the application of the Salter Cyclone Multi-Gravity Separators (“MGS”) technology for the recovery of additional iron ore from the Project.

The completed drilling targeted upgrading the existing Inferred Mineral Resource of 73 million tonnes (Mt) at 6.7% total Fe for 4.9 Mt of contained total Fe to Indicated and to extend the Project to a larger portion of the Adjacent Tailings. The inclusion of the Adjacent Tailings has the potential to almost double the life of mine with no additional capex unlocking substantial upside potential.

Drilling Highlights

• An infill and expansion programme totalling 572 meters of sonic drilling for 12 holes, drilled up to 58 meters, was completed on the historical tailings of the previous Lac Jeannine iron ore mine operated by the Québec Cartier Mining Company between 1959 and 1985.

• Additional bulk sampling has also been concluded, a total of 7 tonnes of tailings and waste rock dumps were recovered to assess their iron content and has been shipped to Corem’s testing facility in Québec.

• Bulk sampling and assay results are expected in Q4 2025.

The Independent Qualified Person as defined by NI 43-101 for the Lac Jeannine Mineral Resource, Mr. Christian Beaulieu, P.Geo., is a member of l’Ordre des géologues du Québec (#1072). The Qualified Person has reviewed and approved the scientific and technical content of this announcement relating to the Lac Jeannine Mineral Resource.

About CoTec
CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) is redefining the future of resource extraction and recycling. Focused on rare earth magnets and strategic materials, CoTec integrates breakthrough technologies with strategic assets to unlock secure, sustainable, and low-cost supply chains for the United States and its allies.

CoTec’s mission is clear: accelerate the energy transition while strengthening U.S. economic and national security. By investing in and deploying disruptive technologies, the Company delivers capital-efficient, scalable solutions that transform marginal assets, tailings, waste streams, and recycled products into high-value critical minerals.

From its HyProMag USA magnet recycling joint venture in Texas, to iron tailings reprocessing in Québec, to next-generation copper and iron solutions backed by global majors, CoTec is building a diversified portfolio with long-term growth, rapid cash flow potential, and high barriers to entry. The result is a game-changing platform at the intersection of technology, sustainability, and strategic materials.

For more information, please visit www.cotec.ca

For further information, please contact:
Braam Jonker – (604) 992-5600

Forward-Looking Information Cautionary Statement
Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” which involve risks and uncertainties, including statements relating to the Lac Jeannine 2025 sonic drilling and bulk sampling testing programme and management’s expectations with respect to other current and potential future investments and the benefits to the Company which may be implied from such statements. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements, due to known and unknown risks and uncertainties affecting the Company, including but not limited to resource and reserve risks; environmental risks and costs; labor costs and shortages; uncertain supply and price fluctuations in materials; increases in energy costs; labor disputes and work stoppages; leasing costs and the availability of equipment; heavy equipment demand and availability; contractor and subcontractor performance issues; worksite safety issues; project delays and cost overruns; extreme weather conditions; and social and transport disruptions. For further details regarding risks and uncertainties facing the Company please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s SEDAR profile at www.sedar.com. The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. Readers should not place undue reliance on the forward-looking statements and information contained in this news release and are encouraged to read the Company’s continuous disclosure documents which are available on SEDAR at www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire

Marathon Returns December 13-14, 2025, Early Registration Now Open

WEST PALM BEACH, FLORIDA / ACCESS Newswire / August 28, 2025 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has agreed to a multi-year partnership as the new title sponsor of The Palm Beaches Marathon. The U.S. Polo Assn. Palm Beaches Marathon, a race owned and managed by Ken Kennerly’s K2 Sports Ventures, will be held in Downtown West Palm Beach, Florida, on December 13-14, 2025.

This renowned marathon event is recognized for its beautiful views of the waterfront and palm-tree-lined streets and welcomes runners from across the country and around the world to the warmth of Florida during the cold winter months. It is also a qualifier for the legendary Boston Marathon.

“U.S. Polo Assn. is honored to be the Title Sponsor of The Palm Beaches Marathon, an iconic event that, like our brand, is deeply rooted in this vibrant community of Palm Beach County,” said J. Michael Prince, President and CEO of USPA Global, the company that oversees the global, multi-billion-dollar U.S. Polo Assn. brand. “While our sport-inspired brand has a worldwide footprint in more than 190 countries, our heart and heritage are right here in The Palm Beaches, home to USPA Global, the United States Polo Association, and the USPA National Polo Center, the most prestigious polo destination in the world.”

The race weekend will include the 5K and 10K at 7:30 a.m. Saturday, December 13, followed by the featured Marathon, Half Marathon, and Marathon Relay on Sunday, December 14 at 6 a.m. Early registration is now open. Cost is $130 for the Marathon and $100 for the Half Marathon. The early registration fee for the 10K is $60, and $45 for the 5K. To register for The U.S. Polo Assn. Palm Beaches Marathon, visit palmbeachmarathon.com.

A Health and Fitness Expo will coincide with race packet pickup on Friday, December 12, from 12 p.m. to 6 p.m. and Saturday, December 13, from 10 a.m. to 6 p.m. at the Meyer Amphitheatre, 104 Datura St., West Palm Beach. The Expo will feature the latest in health and fitness products and services, running apparel, and upcoming race information.

“We are excited to add a renowned global brand like U.S. Polo Assn. as the Title Sponsor of The Palm Beaches Marathon,” Kennerly said. “This is a massive deal for the future of our race and its appeal to runners throughout the world. The Palm Beaches are a globally recognized blue-chip destination, and we are looking forward to continuing to grow the race not only in our community, but also on an international level.”

U.S. Polo Assn. brand products include apparel for men, women, and children, as well as accessories, luggage, watches, shoes, home furnishings, and more, with distribution across 190 countries through independent retail stores, department stores, U.S. Polo Assn. brand stores and e-commerce.

“Partnering with The Palm Beaches Marathon allows us to celebrate athletic excellence, community spirit, health and wellness, as well as the shared passion for sport that connects us locally and around the world. From the polo fields to the streets of Palm Beach, we are inspired by the athletes who give their all, and we look forward to sharing in the energy, camaraderie, and world-class competition that make The Palm Beaches Marathon truly special,” Prince added.

The race will support local charities, soon to be announced.

WPBF 25, the Hearst-owned ABC Affiliate, will return as the Official Broadcast Station of the race and will provide extensive pre- and post-race coverage on all on-air and digital channels, as well as produce a live broadcast on Marathon race morning.

“WPBF 25 is thrilled to extend our partnership for a second year in a row as the Official Broadcast Station of the U.S. Polo Assn. Palm Beaches Marathon, reaffirming our commitment to help bring such a unique and exciting event like this to our community,” said President and General Manager, Caroline Taplett. “Working together with our incredible partners, Ken Kennerly and the Marathon team, we are dedicated to promoting a more connected community, supporting local businesses, and inspiring participants, locally, nationally, and internationally to join us in beautiful South Florida for this one-of-a-kind experience.”

About U.S. Polo Assn.
U.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.

U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn. 

About The U.S. Polo Assn. Palm Beaches Marathon
The U.S. Polo Assn. Palm Beaches Marathon is a premier winter running event held annually in West Palm Beach, which features a range of race distances designed for runners of all abilities, including a full marathon, half marathon, 10K, 5K, and a 4-person marathon relay. Highlighted by a 100% flat, USATF-certified course, the Marathon serves as a Boston Marathon qualifier. The scenic route allows runners to experience West Palm Beach’s vibrant downtown as it winds along palm-lined Flagler Drive, past historic neighborhoods, and features sparkling waterfront views. The event also supports community and charity efforts. Visit palmbeachmarathon.com.

###

SOURCE: U.S. Polo Assn.

View the original press release on ACCESS Newswire

FORT LAUDERDALE, FL / ACCESS Newswire / August 28, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”) a pioneer in high-voltage marine propulsion and multi-brand boat retail, today announced the launch of a dedicated electric boating division within Nautical Ventures Group. This strategic initiative is designed to provide customers with a complete EV-focused experience-encompassing sales, service, after-sales support, events, and a growing lineup of electric toys and watersports products.

The new division is anchored by Vision Marine’s E-Motion™ electric propulsion and electric boat lineup, which serve as the foundation of its EV strategy. As part of this broader initiative, Nautical Ventures has also renewed its Dealer Agreement with Cayago Americas Inc., manufacturer of Seabob. Seabob, known for its electric water sled technology, offers a luxury lifestyle experience and has become internationally recognized as the benchmark for high-end water toys. This aligns with NMMA’s commentary that innovation in product design-especially showcased at leading boat shows-is increasingly important in reigniting consumer demand. (NMMA)

Seabob has already proven to be one of Nautical Ventures’ strongest-selling premium water toys, with the majority of historical sales driven by the F5S model-now succeeded by the new F9 series, which continues to embody the same legacy of innovation. Its performance underscores the proven demand for premium electric lifestyle products that will complement the division’s boat offerings and accelerate adoption of electric marine experiences.

The initiative aligns with broader industry growth. The North American recreational boating market was valued at USD 10.06 billion in 2024 and is projected to reach USD 15.0 billion by 2033, a CAGR of ~4.5% (Market Data Forecast). Within this market, the watersports and accessories segment accounts for over one-third of usage, underscoring the rising importance of lifestyle-driven products. Complementing this, the watercraft accessories market is expected to nearly double-from USD 8.2 billion in 2025 to USD 15.7 billion by 2035-at a 6.1% CAGR (Future Market Insights).

“Our vision goes far beyond propulsion. We are building a complete electric ecosystem for boaters-covering sales, service, aftersales care, and on-water experiences,” said Alexandre Mongeon, Chief Executive Officer and Co-Founder of Vision Marine Technologies. “Through Nautical Ventures, we can unite electric boats, toys, and watersports equipment under one roof. The renewed Seabob dealer agreement demonstrates the type of premium, innovative products we are bringing into this division to complement our boat offerings and deliver unmatched value to consumers and partners.”

The EV-focused division also provides a platform for future collaborations with leading EV partners, setting the stage for upcoming announcements that will highlight synergies across the transportation, marine, and recreation sectors. Leveraging Florida as a natural launchpad, Nautical Ventures will use its nine-location retail and service footprint to accelerate the adoption of electric boating nationwide.

About Vision Marine Technologies Inc.
Vision Marine Technologies Inc. (NASDAQ:VMAR) is a pioneer in the marine industry, offering premium boating experiences across both electric and internal combustion engine (ICE) segments. The Company designs, manufactures, and sells its flagship E-Motion™ 180E high-voltage electric outboard system, while also providing consumers access to boats, marine products, and services through its Nautical Ventures division. With nine retail locations in Florida and established sales, service, and marina operations, Vision Marine delivers scalable, market-ready solutions to meet the evolving needs of recreational boaters and commercial operators.

Official Website
VMAR Investor Presentation

About Seabob (Cayago Americas Inc.)
Seabob, manufactured by Cayago AG and distributed by Cayago Americas Inc., is the world’s leading brand of electric water sleds. Manufactured in Germany and distributed globally, Seabob has become the benchmark in luxury watersports.

Seabob Official Website

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the impact of the EV division launch, the renewed Seabob dealer agreement, anticipated consumer adoption, future collaborations, and the Company’s broader strategic objectives. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Risks include, but are not limited to, market conditions, operational execution, customer demand, competitive factors, and those described in the Company’s SEC filings. Vision Marine disclaims any obligation to update forward-looking statements, except as required by law.

Investor and Company Contact:

Bruce Nurse
Investor Relations
(303) 919‑2913
bn@v‑mti.com

SOURCE: Vision Marine Technologies Inc

View the original press release on ACCESS Newswire

MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / August 27, 2025 / MSC INDUSTRIAL SUPPLY CO. (NYSE:MSM), a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (“MRO”) products and services, today announced the following upcoming investor event:

A real-time audio webcast of MSC’s fireside chat at the Jefferies Industrial Conference can be accessed via the Events and Presentations section of the MSC Industrial Supply Co. Investor Relations website at https://investor.mscdirect.com/events-presentations. A replay of the webcast will be available after the conclusion of the fireside chat and can be accessed on the MSC Industrial Supply Co. Investor Relations website.

# # #

Contact Information

Investors:
Ryan Mills, CFA
Head of Investor Relations
rmills@mscdirect.com

About MSC Industrial Supply Co.

MSC Industrial Supply Co. (NYSE:MSM) is a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (MRO) products and services. We help our customers drive greater productivity, profitability and growth with approximately 2.4 million products, inventory management and other supply chain solutions, and deep expertise from more than 80 years of working with customers across industries. Our experienced team of more than 7,000 associates works with our customers to help drive results for their businesses – from keeping operations running efficiently today to continuously rethinking, retooling and optimizing for a more productive tomorrow. For more information on MSC Industrial, please visit mscdirect.com.

Cautionary Note Regarding Forward-Looking Statements:

Statements in this press release may constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability are forward-looking statements. The words “will,” “may,” “believes,” “anticipates,” “thinks,” “expects,” “estimates,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management’s assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. In addition, new risks may emerge from time to time and it is not possible for management to predict such risks or to assess the impact of such risks on our business or financial results. Accordingly, future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: general economic conditions in the markets in which we operate; changing customer and product mixes; volatility in commodity, energy and labor prices, and the impact of prolonged periods of low, high or rapid inflation; competition, including the adoption by competitors of aggressive pricing strategies or sales methods; industry consolidation and other changes in the industrial distribution sector; the applicability of laws and regulations relating to our status as a supplier to the U.S. government and public sector; the credit risk of our customers; the risk of customer cancellation or rescheduling of orders; our ability to accurately forecast customer demands; customer cancellations or rescheduling of orders; interruptions in our ability to make deliveries to customers; supply chain disruptions; our ability to attract and retain sales and customer service personnel; the risk of loss of key suppliers or contractors or key brands; changes to trade policies or trade relationships; risks associated with opening or expanding our customer fulfillment centers; our ability to estimate the cost of healthcare claims incurred under our self-insurance plan; interruption of operations at our headquarters or customer fulfillment centers; products liability due to the nature of the products that we sell; impairments of goodwill and other indefinite-lived intangible assets; the impact of climate change; operating and financial restrictions imposed by the terms of our material debt instruments; our ability to access additional liquidity; the significant influence that our principal shareholders will continue to have over our decisions; our ability to execute on our E-commerce strategies and maintain our digital platforms; costs associated with maintaining our information technology (“IT”) systems and complying with data privacy laws; our ability to remediate a material weakness in our internal control over financial reporting and to maintain effective internal control over financial reporting and our disclosure controls and procedures in the future; disruptions or breaches of our IT systems or violations of data privacy laws, including such disruptions or breaches in connection with our E-commerce channels; risks related to online payment methods and other online transactions; the retention of key management personnel; litigation risk due to the nature of our business; failure to comply with environmental, health, and safety laws and regulations; and our ability to comply with, and the costs associated with, social and environmental responsibility policies. Additional information concerning these and other risks is described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, and in the other reports and documents that we file with the United States Securities and Exchange Commission. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.

SOURCE: MSC Industrial Direct Co.

View the original press release on ACCESS Newswire

SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 27, 2025 / The YFQ-42A Collaborative Combat Aircraft, designed and developed by General Atomics Aeronautical Systems, Inc. (GA-ASI), is now conducting flight testing in coordination with the U.S. Air Force. This historic achievement continues the company’s rapid creation of new, jet-powered uncrewed platforms chartered by the U.S. Air Force (USAF) to achieve air dominance while being designed for rapid production, in large quantities, at an affordable price.

“What a great moment for the U.S. Air Force and for GA-ASI,” said GA-ASI President David R. Alexander. “It’s been our collaboration that enabled us to build and fly the YFQ-42A in just over a year. It’s an incredible achievement and I salute the Air Force for its vision and I salute our development team for delivering yet another historic first for our company.”

The YFQ-42A is GA-ASI’s newest uncrewed jet, focused on air-to-air semi-autonomous operation and based on the genus-species concept pioneered on the XQ-67A Off-Board Sensing Station (OBSS). Using state-of-the-art, model-based digital engineering, GA-ASI was able to accelerate its schedule while optimizing air dominance capabilities. YFQ-42’s autonomy core has been trained across more than five years of flight testing using GA-ASI’s jet-powered MQ-20 Avenger^®, an aircraft no other company has. The integrated capabilities of a stealthy, air-to-air-focused uncrewed jet, combined with a learned AI autonomy core, provide warfighters with a definitive advantage in the future fight.

The GA-ASI program has focused on creating a high-rate production environment that enables USAF to reach its goal of producing more than 1,000 CCAs on an accelerated timeline. Ground testing for YFQ-42A began in May.

USAF selected GA-ASI in April 2024 to build and fly a fully production-representative Collaborative Combat Aircraft (CCA). In March, USAF designated the aircraft the YFQ-42A, with the “Y” indicating a production-representative aircraft (“Y” will be dropped upon entering production), “F” signifying a fighter aircraft, and “Q” denoting an uncrewed aircraft.

GA-ASI has developed more than two dozen different types of uncrewed aircraft and delivered more than 1,200 units to customers, building more than 100 aircraft per year at its 5 million-square-foot manufacturing facility in Poway, Calif. GA-ASI aircraft have amassed nearly 9 million total flight hours; more than 50 GA-ASI aircraft are aloft around the world every minute of every day.

About GA-ASI

General Atomics Aeronautical Systems, Inc., is the world’s foremost builder of Unmanned Aircraft Systems (UAS). Logging nearly 9 million flight hours, the Predator^® line of UAS has flown for over 30 years and includes MQ-9A Reaper^®, MQ-1C Gray Eagle^®, MQ-20 Avenger^®, and MQ-9B SkyGuardian^®/SeaGuardian^®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.

For more information, visit www.ga-asi.com.

Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc. registered in the United States and/or other countries.

# # #

SOURCE: General Atomics Aeronautical Systems, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax® and mNEXSPIKE®, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.

The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE, Moderna’s new COVID-19 vaccine, is approved for individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. With the U.S. FDA’s decision, Moderna’s updated vaccines are expected to be available in the coming days.

“Protecting people at increased risk of severe outcomes from COVID-19 is imperative to public health as COVID-19 was responsible for up to 4 million outpatient visits and nearly half of a million hospitalizations last year,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are proud to help ensure Americans will have the latest protection against currently circulating strains this respiratory virus season.”

The updated vaccine composition is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be developed with a monovalent JN.1 lineage, with a preference for the LP.8.1 variant.

Moderna’s updated COVID-19 vaccines targeting LP.8.1 have already been granted approval by regulators in Canada, Europe, Japan, Switzerland and other countries. Additional regulatory applications are under review around the world in preparation for the coming season.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Spikevax® and mNEXSPIKE®are registered trademarks of Moderna.

What is mNEXSPIKE® (COVID-19 Vaccine, mRNA) AND SPIKEVAX® (COVID-19 Vaccine, mRNA)?

mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who are:

• 65 years of age and older, or

• 12 years through 64 years of age at high risk for severe COVID-19.

SPIKEVAX is a vaccine to protect against COVID-19. SPIKEVAX is for people who are:

• 65 years of age and older, or

• 6 months through 64 years of age at high risk for severe COVID-19.

Vaccination with mNEXSPIKE or SPIKEVAX may not protect all people who receive the vaccine.

IMPORTANT SAFETY INFORMATION

You or your child should not get mNEXSPIKE® or SPIKEVAX® if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX, any Moderna COVID-19 vaccine, or to any ingredient in these vaccines.

What are the risks of mNEXSPIKE and SPIKEVAX?

There is a very small chance that mNEXSPIKE or SPIKEVAX could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE or SPIKEVAX. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include:

• Trouble breathing

• Swelling of your face and throat

• A fast heartbeat

• A rash all over your body

• Dizziness and weakness

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving mNEXSPIKE or SPIKEVAX, particularly during the 2 weeks after receiving a dose of the vaccine: chest pain, shortness of breath, feelings of having a fast-beating, fluttering, or pounding heart. Additional symptoms in children may include fainting, irritability, poor feeding, lack of energy, vomiting, pain in the abdomen, or cool, pale skin.

Side effects that have been reported in clinical trials with mNEXSPIKE include:

• Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness.

• General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever

Side effects that have been reported in clinical trials with SPIKEVAX include:

• Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection or in the groin, swelling (hardness), and redness

• General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, fever, rash, irritability/crying, sleepiness, and loss of appetite.

• Fainting and febrile seizures (convulsions during a fever) have also been reported

Tell your vaccination provider about all of your or your child’s medical conditions, including if you or your child:

• have any allergies

• had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine

• have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)

• have a fever

• have a bleeding disorder or are on a blood thinner

• are immunocompromised or are on a medicine that affects your immune system

• are pregnant or plan to become pregnant

• are breastfeeding

• have received any other COVID-19 vaccine

• have ever fainted in association with an injection

These may not be all the possible side effects of mNEXSPIKE and SPIKEVAX. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.

Please click for mNEXSPIKE Full Prescribing Information and Information for Recipients and Caregivers.

Please click for SPIKEVAX Full Prescribing Information and Information for Recipients and Caregivers.

Moderna Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the availability of Moderna’s updated COVID vaccines; the efficacy, safety and tolerability of Moderna’s COVID vaccines; and Moderna’s regulatory applications under review around the world. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

A Celebration of Music, Community, and Resilience

BLACK MOUNTAIN, NC / ACCESS Newswire / August 27, 2025 / The Black Mountain Blues Festival is back for 2025, a three-day celebration of music, community, and education. Presented by Black Mountain Blues Society, a new 501(c)(3) nonprofit, the festival takes place Friday, September 26th thru Sunday, September 28th, 2025, in Downtown Black Mountain, NC. The event will feature a vibrant mix of national and regional blues artists in a thriving mountain setting noted for incredible restaurants, one-of-a-kind shopping, and amazing views including access to the Blues Ridge Mountains and Appalachian culture.

Headliners include Robert Randolph, Nik West, Eric Gales, Ra’Shad The Blues Kid, Chambers DesLauriers, and Mac Arnold. The full artist lineup can be found at www.blackmountainblues.org and includes acclaimed local and national musicians, patrons can enjoy educational workshops and special community programming that honors the community’s strength following Hurricane Helene.

Aristotle Jones Band performing during the 2024 Black Mountain Blues Festival – Photography by Bill Green

“Having a lineup with two of Rolling Stone’s top 100 guitar players and a generational bass player is just the beginning. The effort that has gone into helping the Western North Carolina communities have a place to come celebrate resiliency while acknowledging the hardships of the last year is the real story” said Atiba Berkley, Festival Director of Black Mountain Blues Festival.

New this year: 50% of net proceeds from the 2025 festival will be donated to support Hurricane Helene recovery efforts, reinforcing the festival’s mission to uplift and serve the community through music.

Live Music Venues: The festival will take place in the center of downtown Black Mountain, NC. Venues include White Horse Black Mountain, Foothills Grange, Old Town District, Black Mountain Center for the Arts, Peri Social House

Other Experience Partners: Hell Or High Water, Bush Farmhouse, and more.

Huge thanks to our key sponsors: Explore Asheville, AWM Mortgage Swannanoa Blue Mont Stays, Hampton Inn, and RAD (River Arts District Artists)

Crowd at the Bush Farmhouse during the 2024 Black Mountain Blues Festival – Photography by Bill Green

Tickets on sale now!

We look forward to seeing you there! Visit www.blackmountainblues.org to buy tickets and learn more.

Contacts:
Adam Hobbs – Marketing – adam@blackmountainblues.org 828-582-6438
Atiba Berkeley – Festival Director – director@piedmontblues.org
General Inquiries – info@blackmountainblues.org

SOURCE: Black Mountain Blues Festival

View the original press release on ACCESS Newswire